LEARN MORE ABOUT DR. BILAL BIN HAFEEZ

Community NewsNews
1383

Translate to Spanish or other 102 languages!

Graduate research assistants Emmanuel Anning, Godwin Peasah-Darkwah and Asif Shahriar work in the lab to assist in the development of a treatment for advanced pancreatic cancer. (UTRGV Image Office of Research & New Program Development)

Mega Doctor News

- Advertisement -

Hafeez is the founding member of the first nationally recognized South Texas Center of Excellence in Cancer Immunology at the UTRGV School of Medicine and is an accomplished researcher with a background in immunopharmacology, cancer therapeutics and cancer biology. Hafeez, a Nehtaur, Bijnor, Uttar Pradesh, India native, has earned prestigious grant awards and is an active member of the American Association for Cancer Research and the Indian Association for Cancer Research. His significant contributions to cancer biology and molecular therapeutics have led to his numerous published manuscripts in scientific journals. 

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
School of Medicine earns $1.45M grant for pancreatic cancer research
Next article
Nursing and Allied Health to host new conference dedicated to health careers for students

More Articles

DHR Health Recertified for Advanced Hip & Knee Replacements

DHR Health has once again earned The Joint Commission's Advanced Certification in Total Hip and Total Knee Replacement, reaffirming its commitment to providing high-quality, patient-centered orthopedic care to the Rio Grande Valley.

STHS Named to Newsweek’s America’s Greatest Midsize Workplaces for Women

The American workforce is more diverse than ever, with women helping lead that transformation. 

Dysfunctional, Not Missing, Immune Cells Explain Skin Cancer Risk in Immunosuppressed Patients

Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells found in immunocompetent patients, but those cells – known as macrophages – have lost the ability to communicate effectively.

New Study Reveals Real-World Safety Findings for Latest Alzheimer’s Treatment

As new Alzheimer’s drugs move from clinical trials into everyday care, families are asking whether these treatments are safe, how long patients can stay on them, and whether they truly slow the disease outside tightly controlled studies.
- Advertisement -